Bicyclic Amines Inhibit CDK2 to Treat Resistant Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective CDK2 inhibitors, which are crucial for targeting deregulated CDK2 activity in various cancers, leading to uncontrolled cell proliferation and resistance to treatments like trastuzumab and CDK4/6 inhibitors.
Innovation Solution
Development of bicyclic amines that specifically inhibit cyclin-dependent kinase 2 (CDK2) by contacting the enzyme, thereby inhibiting its activity and potentially treating associated cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat cancers with deregulated CDK2 activity, then treatment options are limited, but therapeutic effectiveness is insufficient due to lack of CDK2 inhibition
Solution Approach 1:
The patent segments the broad category of CDK inhibitors into specific CDK2-targeting compounds with distinct chemical structures (bicyclic amine core with specific substituents). This segmentation allows for selective CDK2 inhibition while distinguishing from other CDK family members, thereby improving therapeutic effectiveness for CDK2-driven cancers without compromising treatment versatility
Solution Approach 2:
The patent employs parameter changes by optimizing specific molecular parameters of the bicyclic amine compounds (substituent types at R1-R6 positions, ring saturation, heteroatom placement) to achieve desired CDK2 inhibitory potency and selectivity. This systematic parameter optimization enables effective CDK2 targeting while maintaining adaptability across different cancer types and resistance scenarios
2Productivity
If CDK2 activity is not inhibited, then cell proliferation continues uncontrolled, but existing therapies cannot effectively target CDK2
Solution Approach 1:
The bicyclic amine compounds act as intermediary molecules that specifically bind to and inhibit CDK2, thereby mediating control over cell proliferation. These compounds serve as the missing link between therapeutic intervention and CDK2 enzyme inhibition, enabling effective suppression of uncontrolled cell division in CDK2-driven cancers
Solution Approach 2:
The patent optimizes molecular parameters of the bicyclic amine structure (core ring system, substituent positions R1-R6, heteroatom configuration) to achieve potent and selective CDK2 inhibition. This parameter optimization ensures reliable therapeutic effectiveness by maintaining sufficient inhibitory potency against CDK2 while controlling off-target effects
3Adaptability or versatility
If cancers develop resistance to trastuzumab and CDK4/6 inhibitors, then treatment options are reduced, but underlying CDK2 deregulation remains unaddressed
Solution Approach 1:
The patent extracts and addresses the specific CDK2 inhibition need that is missing from current therapy regimens. By isolating CDK2 as the specific target and developing dedicated inhibitors, the patent provides a complementary treatment approach that can be combined with or used alternative to trastuzumab and CDK4/6 inhibitors, thereby managing resistance while maintaining treatment efficacy
Solution Approach 2:
The bicyclic amine compounds exhibit universal applicability across multiple cancer types and resistance scenarios by specifically targeting CDK2, which is deregulated in various malignancies. This multi-functional approach allows the same CDK2 inhibitors to address diverse clinical situations including trastuzumab resistance and CDK4/6 inhibitor resistance, thereby improving both adaptability and reliability
Data Source
AI summary
The present application provides bicyclic amines of Formula (I):and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.